Conflicts of Interest in Medicine: From Individual Clinical Management to Population-Level Governance

Conflicts of interest (COI) in medicine are often discussed as a general threat to the integrity of clinical practice and health policy. However, their implications may differ substantially according to the level and reversibility of the decisions involved. This opinion article examines this distinction by comparing COI in the management of lifestyle-related diseases with those arising in infectious disease policy, particularly during the COVID-19 pandemic. In routine clinical care, potential biases in guideline development or pharmaceutical relationships do not necessarily negate the established biological efficacy of medications. Moreover, treatment decisions can often be individualized through adjustment of drug selection and dosage, monitoring of adverse effects, deprescribing, and shared decision-making. Thus, although COI and excessive healthcare expenditures warrant scrutiny, potential harms can frequently be mitigated at the patient level. By contrast, population-wide infectious disease policies, including mass vaccination campaigns and restrictions on social activities, can involve substantial public expenditure and far-reaching consequences for healthcare access, education, the economy, mental health, and mortality. Because individuals may have limited opportunities to opt out of or reverse such interventions, inadequate transparency, insufficient cost-effectiveness assessment, or structural COI may result in socially irreversible harms. Although rapid decision-making may be unavoidable during emergencies, this does not eliminate the need for subsequent disclosure of evidence, reassessment of effectiveness and harms, and open evaluation of competing hypotheses. Accordingly, COI should not be regarded as a universal explanation for problems in medicine. Greater scrutiny is particularly warranted when macro-level policy decisions have extensive and potentially irreversible societal consequences. Transparent, evidence-based, and accountable governance is essential for correcting policies when necessary and maintaining public trust in health policy and science.